Home/Pipeline/VAXINIA (CF33-hNIS)

VAXINIA (CF33-hNIS)

Advanced or metastatic solid tumors

Phase 1Active

Key Facts

Indication

Advanced or metastatic solid tumors

Phase

Phase 1

Status

Active

Company

Imugene

About Imugene

Imugene is focused on developing next-generation immunotherapies that aim to stimulate the body's immune system to fight cancer. Its core technology platforms include oncolytic virotherapy (CF33), B-cell immunotherapy (HER-Vaxx), and checkpoint inhibitor therapies. The company has multiple candidates in clinical development, primarily targeting gastrointestinal cancers and other solid tumors, and operates through strategic collaborations with leading cancer research institutions.

View full company profile

Therapeutic Areas

Oncology Immuno-oncology

Other Advanced or metastatic solid tumors Drugs

Drug	Company	Phase	Status
PRT3645	Prelude Therapeutics	Phase 1	Active
CHECKvacc (CF33-hNIS-antiPDL1)	Imugene	Phase 1	Active
WTX-124	Werewolf Therapeutics	Phase 1	Active